Richard Weil
CEO at JANUS HENDERSON INVESTORS
Investor
Deal Bio
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.
Expertise (31)
Key Relationships
Sort
FREENOME
T. Rowe Price Group
£126m
30 dealmakers
Everest Medicines
Octagon Investments
£245m
18 dealmakers
Shattuck Labs
Hatteras Venture Partners
£94m
15 dealmakers
Chinook Therapeutics
Ecor1 Capital
£80m
ANNEXON
Adage Capital Management
£81m
16 dealmakers
C4 Therapeutics
Rtw Investments
£119m
26 dealmakers
Velosbio
Cormorant Asset Management
£105m
BIOATLA
Soleus Capital
£55m
14 dealmakers
Iteos Therapeutics
The Invus Group
£101m
25 dealmakers
Neurogene
Casdin Capital
£85m
Day One Biopharmaceuticals
Ra Capital Management
11 dealmakers
Centessa Pharmaceuticals
Janus Henderson Investors
£179m
27 dealmakers
Xos
Nextgen Acquisition Corp.
£1,426m
40 dealmakers
Artiva Biotherapeutics
Acuta Capital
value n/a
SOMALOGIC
£891m
63 dealmakers
Grab Holdings
Temasek Holdings
£28,839m
101 dealmakers
Tango Therapeutics
£257m
32 dealmakers
Icosavax
Sanofi Ventures
£71m
19 dealmakers
INIVATA
NEOGENOMICS
£281m
41 dealmakers
P3 Health Partners
£1,624m
Nikang Therapeutics
Surveyor Capital
£141m
29 dealmakers
Wallbox
Cathay Innovation
£1,059m
64 dealmakers
SYNTHEKINE
£75m
13 dealmakers
Mirion Technologies
Neuberger Berman Group
£1,847m
90 dealmakers
Element Biosciences
Counterpoint Global - Morgan Stanley
£198m
12 dealmakers
Lexeo Therapeutics
D1 Capital Partners
£72m
Avidity Partners
£144m
Chroma Medicine
Atlas Venture
£93m
PHARMEASY
Apah Capital
£255m
LOADSMART
Softbank Latin American Fund
£148m
10 dealmakers
INTELYCARE
Leeds Illuminate
£87m